Table 2 DLBCL patient characteristics by HIV infection status

|  |  |  |  |
| --- | --- | --- | --- |
| characteristics | HIV-infected（N=27） | HIV-uninfected（N=27） | P |
| age in years, mean (SD) | 48.9 (12.3) | 48.2 (12.4) | 0.852 |
| male agenda | 25 (92.6%) | 22 (81.5%) | 0.224 |
| International Prognostic Index (IPI) |  |  |  |
| 1~2 | 16 (59.3%) | 18 (66.7%) | 0.779 |
| 3~4 | 11 (40.7%) | 9 (33.3%) |  |
| CD4 cell count at DLBCL diagnosis, cells/mm3, mean (SD) | 225.9(95.4) | 227.8 (91.8) | 0.942 |
| overexpression of BCL-2 protein |  |  |  |
| yes | 7 (25.9%) | 19 (70.4%) | 0.001 |
| no | 20 (74.1%) | 8 (29.6%) |  |
| overexpression of c-MYC protein |  |  |  |
| yes | 10 (37%) | 14 (51.9%) | 0.273 |
| no | 17 (63%) | 13 (48.1%) |  |
| Cell-of-origin phenotype |  |  |  |
| Germinal center (GC) | 18 (66.7%) | 11 (40.7%) | 0.056 |
| Non-GC | 9 (33.3%) | 16 (59.3%) |  |
| absolute lymphocyte value |  |  |  |
| ≥1 | 12 (44.4%) | 12 (44.4%) | 1 |
| <1 | 15 (55.6%) | 15 (55.6%) |  |
| Efficacy evaluation (evaluation of efficacy after 6 cycles of chemotherapy) |  |  |  |
| complete response (CR) | 13 (48.1%) | 7 (25.9%) | 0.189 |
| partial response (PR) | 10 (37.0%) | 15 (55.6%) |  |
| stable disease (SD) | 0 (0%) | 3 (11.1%) |  |
| progressive disease (PD) | 4 (14.8%) | 2 (7.4%) |  |
| one-year survival |  |  |  |
| yes | 17 (63.0%) | 25 (92.6%) | 0.023 |
| no | 8 (29.6%) | 2 (7.4%) |  |
| not reached | 2 (7.4%) | 0 (0%) |  |